Kaufmann, Elisa M.
Krause, Sven
Geisshuesler, Lukas
Scheidegger, Olivier
Haeberlin, Andreas
Niederhauser, Thomas
Funding for this research was provided by:
Berner Fachhochschule (Research Grant for Doctoral Students)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (CRSK − 3190637/1)
Article History
Received: 22 September 2022
Accepted: 18 January 2023
First Online: 30 January 2023
Declarations
:
: The animal studies were conducted in accordance with the principles of laboratory animal care and were approved by the Committee of the Cantonal Animal Experiments Commission of Bern and conducted in collaboration with the Department for Biomedical Research (DBMR) of the University of Bern.
: All authots and coauthors provided consent.
: Dr. Haeberlin has received research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, the University of Bern, the University Hospital Bern, the Velux Foundation, the Hasler Foundation, the Swiss Heart Rhythm Foundation, and the Novartis Research Foundation. He is Co-founder and CEO of Act-Inno, a cardiovascular device testing company. He has received travel fees/educational grants from Medtronic, Philips/Spectranetics and Cairdac without impact on his personal remuneration.